CORBUS PHARMACEUTICALS HOLDINGS, INC. (NASDAQ:CRBP) Files An 8-K Other EventsItem 8.01 Other Events.
On November 27, 2017, Corbus Pharmaceuticals Holdings, Inc. (the “Company”) closed the sale of 697,500 newly issued shares (the “Option Shares”) of the Company’s common stock, par value $0.0001, at a price to the public of $7.00 per share to the exercise in full of the 30-day option (the “Option”) granted to the underwriters under the previously announced underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co., as representative to the several underwriters named therein. The Company received net proceeds from the exercise of the Option of approximately $4.6 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.
A description of the material terms of the Underwriting Agreement was previously reported in Item 1.01 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 24, 2017, and the information set forth in such Item 1.01 is incorporated herein by reference.
On November 27, 2017, the Company issued a press release regarding the closing of the sale of the Option Shares. A copy of the press release is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Corbus Pharmaceuticals Holdings, Inc. ExhibitEX-99.1 2 ex99-1.htm Exhibit 99.1 Corbus Pharmaceuticals Holdings,…To view the full exhibit click here
About CORBUS PHARMACEUTICALS HOLDINGS, INC. (NASDAQ:CRBP)
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases. The Company’s segment is developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases. Its product, Resunab, is a synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. Resunab is being evaluated in approximately three separate Phase II studies for the treatment of cystic fibrosis, systemic sclerosis and skin-predominant dermatomyositis. The United States Food and Drug Administration has granted Resunab Orphan Drug Designation, as well as Fast Track Status, for both cystic fibrosis and systemic sclerosis. Resunab is in Phase II clinical stage for the treatment of Systemic Lupus Erythematosus.
